Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMRPCF2)

• Drug Name: MGCD265 Drug Info
• Synonyms: MGCD-265; 875337-44-3; MGCD265; MGCD-265 analog; MGCD 265; N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; UNII-93M6577H9D; CHEMBL254760; 93M6577H9D; n-(3-fluoro-4-(2-(1-methyl-1h-imidazol-4-yl)thieno(3,2-b)pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide; N-[(3-Fluoro-4-{[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-phenylacetamide

Indication

Disease Entry	ICD 11	Status	REF
Non-small-cell lung cancer	2C25.Y	Phase 2	[1]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID:
  PubChem CID: 24901704
  ChEBI ID: CHEBI:91393
  CAS Number: CAS 875337-44-3
  TTD Drug ID: DMRPCF2

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein kinase (PK)	TTU8W4S	NOUNIPROTAC	Inhibitor	[2]
Tyrosine-protein kinase UFO (AXL)	TTZPY6J	UFO_HUMAN	Modulator	[3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Tyrosine-protein kinase UFO (AXL)	DTT	AXL	6.677	7.261	6.33	7.021

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

• The Studied Disease: Non-small-cell lung cancer
• ICD Disease Classification: 2C25.Y

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tyrosine-protein kinase UFO (AXL)	DTT	AXL	1.13E-65	-0.53	-2.04

References

• [1] ClinicalTrials.gov (NCT02544633) Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Company report (Mirati Therapeutics: formerly MethylGene)